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Background: Cisplatin (CIS) is one of the most effective anticancer drug used in the treatment of several solid
tumors .Its use is limited by its nephrotoxicity. The present study was designed to assess the role of a natural
product resveratrol (RSVL) on sensitization of mammary carcinoma (Ehrlich ascites carcinoma) to the action of CIS
and the possible protective effect against CIS-induced nephrotoxicity in rats.
Methods: The percent survival of female tumor bearing mice was used for determination the cytotoxic activity of
CIS in the presence or the absence of RSVL. Uptake and cell cycle effect, serum creatinine (CREA), blood urea
nitrogen (BUN), Reduced Glutathione (GSH) and histopatholgical examination of kidney tissues after CIS and/or
RSVL therapy were also investigated.
Results: RSVL increased the intracellular level of CIS in EAC cells and there was a strong correlation between the
high cellular level of CIS and its cytotoxicity. CIS at a dose level of 5 mg/kg increased the mean survival time of
female tumor bearing mice to 25 days compared with 17 days for tumor-bearing control mice. Administration
of RSVL at a dose level of 25 mg/kg simultaneously with CIS increased the mean survival time to 48 days with
60% survival of the tumor-bearing animals. Cell cycle analysis of tumor cells showed that CIS treatment decreases
the proliferation index of tumor cells while in presence of RSVL there was more significant inhibitions. Also, CIS
treatment caused increase in level of creatinine and blood urea with significant decrease in the GSH level. While,
in the presence of RSVL, level of creatinine and blood urea restored to control level.
Conclusion: This study suggests that RSVL could increase the cytotoxic activity of CIS and protect against its
nephrotoxicity.
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Cisplatin is commonly used cytotoxic drug in the man-
agement of several human solid tumors such as neck
and head, testis, ovary, bladder, colorectal and breast
cancers. Whilst early good responses to drug after the
first cycles of the treatment, CIS usually acquired resist-
ance and severe toxicity including renal, neuro, oto, gas-
tro toxicity as well as myelosuppression [1]. It has been
reported that reactive oxygen species (ROS) play an im-
portant role in CIS-triggered acute renal failure [2], and* Correspondence: moneimosman@hotmail.com
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unless otherwise stated.also trigger depletion of glutathione which play a role in
nephrotoxicity [3,4]. The alternative strategy is to develop
co-therapies that reduce renal damage by counteracting
CIS effects on the kidney. In an attempt to minimize the
serious side effects of anticancer drugs ,a variety of
approaches have been investigated. A natural product like
resveratrol (RSVL) which have an additive cytotoxic activ-
ity has been tried with different type of anti-cancer drugs
against different cancer cells [5]. Resveratrol is one of
promising dietary chemopreventive phytochemicals che-
motherapeutic potential. It has wide-spectrum beneficial
effect, such as anti-infective, anti-oxidant and cardiopro-
tective function [6]. In light of these findings the goal
of this study is to examine the possible effect of RSVL
treatment in enhancing the antitumor activity of CIS by. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Effects of CIS and/or RSVL treatment on the






Control 17 ± 3.74 0/10
RSVL (25 mg/kg) 12 ± 5.95b 0/10
CIS (5 mg/kg) 25 ± 12.13 2/10
CIS (5 mg/kg) + RSVL (25 mg/kg)
(supplied simultaneously)
48 ± 15.03a,b 6/10
Each data represents the mean ± S.D. of ten mice.
aSignificantly different from control at P-value < 0.05. bSignificantly different
from CIS at P-value < 0.05.
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tion. In addition, examining the possible renal protective
effect of RSVL against CIS triggered nephrotoxicity.
Materials and methods
Drugs and chemicals
Cisplatin (CIS) and resveratrol (RSVL) were purchased
from Sigma Aldrich Co. (Saint Louis, Missouri, USA).
The stock solution of both drugs (dissolved in phosphate
buffer saline (PBS) and preserved at −20°C). The solutions
were diluted in normal saline immediately before each
experiment to the desired final concentration.
Animals and tumor
Female Swiss albino mice (8 weeks of age, 20–22 g body
weight) and Female Wistar albino rats (8–10 weeks of
age, 180-200 g body weight) were obtained from King
Fahd Medical Research center, King Abdulaziz University,
Jeddah, Saudi Arabia. The animals were acclimatized for
one week before each experiment. A commercial balanced
diet and water ad libitum were provided throughout the
experiment.
The Ehrlich ascites carcinoma cells (EAC) cells was
acquired through the courtesy of National cancer insti-
tute (Cairo) and maintained in our laboratory by weekly
I.P. transplantation of 2.5 × 106 cells/mouse. This study
was approved by the Institutional ethical committee of
King Abdulaziz hospital.
Evaluation of antitumor activity
The effect of RSVL on the antitumor activity of CIS
against the growth of EAC was evaluated using the
modified regimen of Donenko et al. [7]. Ehrlich ascites
carcinoma cells were inoculated i.p. into forty Swiss
albino mice (20–22 g) 2.5 × 106 cells/mouse. Twenty four
hours later, mice were equally divided into four groups.
Group I injected with normal saline i.p. (0.2 ml/20 gm)
and served as control group. Group II was administered
with CIS (5 mg/kg i.p.) while group III received a single
dose of RSVL (25 mg/kg i.p.). Group IV received RSVL
(25 mg/kg i.p.) simultaneously with CIS (5 mg/kg i.p.).
Average survival days of mice and long term survivors
are defined as the mice survived to the end of the experi-
ment (45 days) with no apparent tumor.
Measurement of Cisplatin cellular uptake
CIS cellular accumulation assessment in Ehrlich ascites
cells was performed using ICP-Optical Emission Spec-
trometer (Optima 7000 DV ICP-OES perkinelmer, Inc.
Waltham, USA). EAC cells were inoculated i.p. into
thirty six Swiss albino mice (20–22 g) 10 × 106 cells/
mouse. Twenty four hours later, mice were divided into
six groups (six mice each). Groups 1,2 and 3 injected
with CIS (7.5 mg/kg, i.p.). while, groups 4, 5 and 6injected with RSVL (25 mg/kg, i.p.) simultaneously with
CIS (7.5 mg/kg, i.p.). Animals were sacrificed by cervical
dislocation at 3, 24 and 48 hours after treatment. Cell
withdrawn from peritoneal cavity and washed twice with
PBS and then suspended in 1 ml of normal salain. Then,
centrifuged at 5000 rpm for 20 minute and washed
once by PBS. Cells were counted and 2 ml of 1% nitric
acid were added to the samples and kept in oven at 70
C for 24 hours. The volume of samples were completed
to 5 ml with PBS then CIS concentration measured by
ICP-Optical Emission Spectrometer (Optima 7000 DV
ICP-OES PerkinElmer, Inc. Waltham, USA) at wave-
lengths 203 nm, 210 nm and 214 nm, respectively. Cell-
uptake platinum was expressed as ppt of platinum per
1 × 106 cells.
Cell cycle analysis
Ehrlich ascites carcinoma cells were inoculated i.p. into
sixty Swiss albino mice (20–22 g) 10 × 106 cells/mouse
and processed as mentioned above. Tumor cells were
obtained at fixed times after CIS treatment. Cell cycle
analysis was performed using flow cytometer (Becto
Dicknson, BD, FACScalbur, USA according to the method
of Smets et al. [8].
Nephrotoxic effect of CIS in presence of RSVL
Fifty six female Wister rat were divided into four equal
groups, each composed of fourteen animals each. Groups
I received normal saline i.p. (0.5 ml/200 gm) and served as
control group. Group II received RSVL (25 mg/kg body
weight, i.p.). Group III received a single dose of CIS
(7.5 mg/kg body weight, i.p.). Group IV received RSVL
(25 mg/kg body weight, i.p.) and CIS (7.5 mg/kg body
weight, i.p.) simultaneously. At the end of experiment
period (48 hours), rat were anesthetized and blood
samples were collected from 5 animals from each group
from the ophthalmic artery in the orbital rim and rapidly
centrifuged for Serum separation then stored at −80°C to
evaluate serum creatinine (CREA) and blood urea nitro-


















Figure 1 Effects of CIS and/or RSVL treatment on the antitumor activity of CIS in mice bearing Ehrlich ascites carcinoma cell.
Osman et al. Cancer Cell International  (2015) 15:6 Page 3 of 8(Siemens healthcare diagnostics ltd, USA) by Dimension
Vista 1500 Intelligent Lab System (Siemens, USA) accord-
ing to manufacturer instructions. kidney specimens from
each groups (3 animals) were fixed in 10% formalin for
light microscopic study. The residual kidney pieces (6 ani-
mals) was weighted and homogenized in 7 ml cold buffer
(50 mM potassium phosphate, pH 7.5, 1 mM EDTA) per
gram tissue by Homogenizer (Potters, German) then it
was centrifuged at 4000 rpm for 15 minutes at 4°C. The
supernatant was removed and stored in −80°C and used
for the evaluation of reduced glutathione (GSH) by colori-
metric method using biodiagnostic kit (Biodiagnositc,
Egypt), according to the method of Beutler et al., [9].
Statistical analysis
Statistical analysis was performed using SPSS (Statistical


















CIS (7.5mg/kg) + RSVL
(25mg/kg)
Figure 2 Effect of RSVL treatment on the CIS cellular uptake in EAC c
mice, (Red square) CIS and RSVL (25 mg/kg) in simultaneous manner. Data
Corresponding CIS after 3 hrs.of treatment at P > 0.05. bsignificantly different f
different from Corresponding CIS after 48 hrs.of treatment at P > 0.05.of variance (ANOVA) followed by least significant differ-
ence (LSD) for post hoc analysis was used for multiple
comparisons. Statistical significance was acceptable to a
level of p ≤ 0.05.Results
Survival of tumor bearing mice
Table 1 and Figure 1 show the effect of treatment with
CIS and/or RSVL on the survival of tumor bearing mice.
Tumor-bearing control mice showed mean survival time
of 17 days, whereas ,administration of a single dose of
CIS (5 mg/kg,i.p.) increased the mean survival time to
25 days, with 20% long term survivors. Simultaneous
treatment with RSVL (25 mg/kg) significantly increased
the mean survival time of tumor-bearing mice to 48 days
with 60% survivors.3h 24h 48h
Hrs. after CIS treatment
ells. (Blue Diamond) CIS was injected (7.5 mg/kg) in tumor-bearing
represents the mean ± S.D. of six mice. aSignificantly different from
rom Corresponding CIS after 24 hrs.of treatment at P > 0.05. cSignificantly
Figure 3 Effect of CIS and/or RSVL treatment on cell cycle phase distribution of EAC cells. Cell cycle distribution was analyzed after 3 hrs.
of exposure to drugs by staining with propidium iodide. (A) Control), (B) Cells treated with RSVL (25 mg/kg). (C) Cells treated with CIS (7.5 mg/kg).
(D) Cells treated with CIS (7.5 mg/kg) and RSVL (25 mg/kg).
Table 2 Effect of CIS and/or RSVL on proliferative activity
of EAC cells
Time after treatment
Groups 3 hrs. 24 hrs. 48 hrs.
Control 59.99 ± 1.38
RSVL (25 mg/kg) 48.89a ± 2.02 46.87a,b ± 2.14 48.20a,b ± 2.07
CIS (7.5 mg/kg) 50.23a ± 4.73 36.93a ± 3.05 37.20a ± 1.96
CIS (7.5 mg/kg) +
RSVL (25 mg/kg)
28.56a,b ± 4.29 16.79a,b ± 3.43 27.78a,b ± 2.89
Data represents the mean ± S.D. of six mice. aSignificantly different from Control at
P > 0.05. bSignificantly different from corresponding treatment of CIS at P > 0.05.
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Figure 2 show the cellular level of CIS in Ehrlich ascites
cells after a single dose of CIS (7.5 mg/kg,i.p.) and/or
RSVL (25 mg/kg,i.p.). All the time point tested showed that
simultaneous RSVL treatment significantly increased the
cellular uptake of CIS in the tumor cells with maximum
level 24 hours after treatment (about 5.6 fold increase).
Effect of CIS and /or RSVL treatment on cell cycle phase
progression in Ehrlich cells
CIS treatment (7.5 mg/kg) accumulated the dead cells in
Sub-G1 phase by 6% after 3 hrs. of treatment, while
combination treatment of CIS and RSVL showed more
significantly accumulation of the dead cells in Sub-G1
phase by 23.58% after 3 hrs. with maximum accumula-
tion after 24 hrs. (data not shown). Moreover, there was
more arrest in G0/G1 phase with maximum arrest after 3
hrs. by about 47.85% compared to control (Figure 3).
Three, 24 and 48 hours after CIS treatment the prolifer-
ation index (S phase + G2/M phase) inhibited by about
16.38,38 and 38%, respectively (Table 2). Concomitant
treatment with RSVL reduced the proliferation index
significantly by about 52, 72 and 54%, respectively.
Protective effect of RSVL against CIS-induced nephrotoxicity
Treatment of rats with CIS (7.5 mg/kg,i.p.) caused a
significant 3 and 5 fold increase in serum creatinine andblood urea nitrogen, respectively. Simultaneous treat-
ment with RSVL (25 mg/kg,i.p.) reduced the adverse
effect of CIS by about 2 and 1.3 fold, respectively
(Table 3). Light microscopic examination of kidney
section of albino rats after a single dose of CIS showed
cortex with shrunken capillary tuft of the glomerulus
and widening of the subcapsular space (double head arrow)
with deposition of homogenous material (casts) in their
lumen (star) and intertubuluar congestion (white arrow)
(Figure 4). Concomitant administration of RSVL with
CIS showed cortex with normal glomerulus (G), dilated
tubules (black arrow) and flaking of cells into tubular
lumen (Figure 5). RSVL alone showed a general architec-
ture almost similar to control (Figures 6 and 7). Figure 8
show effect of CIS and/or RSVL on reduced glutathione
Table 3 Effect of CIS and/or RSVL on the serum level of





Control 32 ± 2.92 2.12 ± 0.72
RSVL (25 mg/kg) 35 ± 1.58 3 b ± 0.73
CIS (7.5 mg/kg) 93 a ± 10.32 11 a ± 0.79
CIS (7.5 mg/kg) + RSVL
(25 mg/kg)
45 a,b ± 2.55 8 a,b ± 1.16
Data are presented as mean ± S.D of five rats.
aSignificantly different from control at P > 0.05. bSignificantly different from CIS
at P > 0.05.
Osman et al. Cancer Cell International  (2015) 15:6 Page 5 of 8(GSH) activity in rat kidney homogenate. CIS (7.5 mg/kg)
treatment showed a significant decrease in level of GSH
by 63.4% compared to control. While, in presence of
RSVL (25 mg\kg), the GSH level increased.Discussion
Cisplatin continues to be widely used as a main cancer
drug due to its disparity antitumor activity when com-




Figure 4 Photomicrographs of sections of the kidney of a rat treated
glomerulus(G) and widening of the subcapsular space (double head a
(black arrows), deposition of homogenous material (casts) in their lumen (s
cytoplasm (arrows) of both proximal (P) and distal (D) convoluted tubules.other dividing cells, CIS-DNA intrastrand crosslinks
result in cytotoxicity [10].
Recent studies have discovered new protocols, com-
pounds, enzymes and molecular alterations that reduced
the side effect of anticancer drugs and enhanced their cyto-
toxic effects [11-13].
In an attempt to minimize CIS side effects and at the
same time increasing its anticancer efficacy, we investigated
whether RSVL which is a naturally occurring compound
that is found in many food like grapes, can enhance the
cytotoxic activity of CIS against the growth of EAC cells
in vivo and the possible protective role against CIS-induce
nephrotoxicity.
In the current study treatment of tumor bearing mice
with RSVL (25 mg/kg) enhanced the cytotoxic activity of
CIS against the growth of EAC cells with 2.92 folds
increase in long-term survivor. It seems that RSVL did
not show anti-tumor activity by its own, but rather in-
creased the anti-tumor activity of CIS against the growth
of EAC cells (Figure 1 and Table 1)). Combining resvera-
trol with CIS is a novel strategy that has the potential for
improving the antineoplastic activity of CIS [14]. It has
been reported that a greatest synergism was observed2b
D
with CIS showing (2a) cortex with shrunken capillary tuft of the
rrow). (2b) deeper cortex with desquamated tubular epithelium




Figure 5 Photomicrographs of sections of the kidney of a rat treated with RSVL and CIS simultaneously showing (4a) the cortex with
normal glomerulus (G), dilated tubules (black arrow) and flaking of cells into tubular lumen (white triangles) (4b) deeper cortex
revealing intratubular homogenous cast material (stars).
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platinum drug (CIS or oxaliplatin) 2 hr later [15]. High
cellular level of CIS concentrations in EAC cells has been
observed when RSVL was concomitantly administered
with CIS (Table 2).This is in a good agreement with previ-
ous work in our laboratory, when human breast cancer
cell line MCF-7 was treated with simultaneous combin-
ation of RSVL and anti-cancer drug DOX resulted in
more DOX cellular uptake [5]. The increase in CIS cel-
lular uptake inside Ehrlich cells may be explained by in-
hibition of P-gp that plays very important role in the
absorption, distribution, and elimination of anticancer
drug and thus determine its efficacy and toxicity. There
were many reports showed that the inhibition of P-gp
considered as one of the mechanism of RSVL chemosensi-
tizing effect to anticancer drugs [16,17].
On contrary to our work, yang et al., [18] reported
that RSVL enhanced the activity of P-gp in colon cancer1a 1
Figure 6 Photomicrographs of sections of the kidney of a rat of the c
glomeruli (G) and subcapsular space (arrows). (b) deeper cortex with p
eosinophilic cytoplasm and round basal nuclei (black arrow).cell line. These conflicting findings could be explained
on the following basis: MDR can be acquired after initial
exposure to the anticancer drugs [19]. In addition several
studies have found that some of the well-known P-gp an-
tagonists such as verapamil and cyclosporine A can induce
P-gp expression in colon carcinoma cells [20]. So, it is im-
portant to know that the time needed for expression and
inhibition of P-gp by their antagonists is controversial.
It is well known that DNA damage caused by different
cytotoxic agents, induce cell cycle arrest at G0-G1, S and
G2-M phases, thereby preventing replication of damaged
DNA or aberrant mitosis which if not repaired, may result
in either tumorigenesis or apoptosis [21,22].
In our work, simultaneous treatment of CIS with RSVL
significantly accumulated EAC cells in sub-G1phase and
arrested the cells in G0/G1chek point. The arrest of cells in
S phase significantly decreased compared with treatment
with CIS alone, which means more cells left the cycle afterb
P
D
ontrol group showing (1a) cortex with normal structured




Figure 7 Photomicrographs of sections of the kidney of a rat treated with RSVL showing (3a) the cortex with normal structure of the
glomerulus (G) and evident intertubular congestion (arrows). (3b) deeper cortex with dilated proximal (P) and distal (D) convoluted
tubules (arrows).
Osman et al. Cancer Cell International  (2015) 15:6 Page 7 of 8G0/G1 check point or S phase and entered the apoptotic
sub-G1 phase. These result are in agreement with others
that investigated the role of RSVL in modulating CIS
cytotoxicity by enhanced growth inhibition which may
be due to ability of RSVL to induce apoptotic reaction
through activation of proapoptotic family members, which
works together with cytotoxic effect of chemotherapy
agents [13].
Moreover, cell cycle analysis showed that treatment
with RSVL plus CIS induced a significantly decrease in
the proliferation index (S phase + G2/M phase) compared
with cells treated with CIS alone, with maximum decrease
after 24 hours. This agrees with the uptake study where
cisplatin uptake in tumor cells was increased after
addition of RSVL with maximum level observed after
24 hours (Table 2). It has been known that the nephrotox-





























Figure 8 Effect of CIS and/or RSVL on reduced glutathione (GSH) leve
six rats. aSignificantly different from control at P > 0.05. bSignificantly differeResearch into the mechanism of CIS nephrotoxicity is
an important step for renal protection. One theory involve
binding of CIS to sulfhydryl (SH) groups in the kidneys
are necessary for enzyme function and depletion of
intracellular glutathione lead to renal damage [25]. In
agreement with that work our study showed that RSVL
treatment inhibited CIS-induced depletion in GSH and
protected against CIS induced nephrotoxicity that man-
ifested by restoration of CREA. and BUN to normal
level after CIS and RSVL treatment.
It is well known that CIS can cause oxidative stress by
suppress cellular antioxidants defenses due to its binding
to nucleophilic molecules such as glutathione, methionine
or cysteine-rich proteins [26]. At the same time RSVL had
ability to suppress of oxidative stress so could prevent CIS
induced organ toxicity [13,27].
Light microscopic study confirmed the biochemical find-
ings, where the kidney in rat treated with RSVL and CISrol Cispla n CIS + RSVL
Treatment
l in rat kidney homogenate. Each value presented as mean ± S.D of
nt from CIS at P > 0.05.
Osman et al. Cancer Cell International  (2015) 15:6 Page 8 of 8simultaneously showed the cortex with normal glomerulus.
Also, the electron microscopic study (data not shown)
confirmed these results where simultaneous treatment of
CIS with RSVL showed organized apical microvilli, mito-
chondria and spaces between the cytoplasmic infolding
appear within normal and nuclei appear euchromatic.
In conclusion, we demonstrated that RSVL treatment
significantly has a potential role in enhancing the antitu-
mor activity of CIS with renal protective effect against
its nephrotoxicity.
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